SCHEMBL2712934

SCHEMBL2712934

CC(C(O)c1ccccc1)N1CCCCC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 6/20 0.55
KCNH2 Q12809 6/20 0.55
CYP1A2 P05177 5/20 0.55
CYP3A4 P08684 5/20 0.55
CYP2C9 P11712 4/20 0.55
KCNA5 P22460 4/20 0.55
CYP2C19 P33261 4/20 0.55
KCNE1 P15382 1/20 0.55
MAOB P27338 1/20 0.53
GRIN2B Q13224 6/20 0.52
GRIN1 Q05586 4/20 0.52
GRIN2D O15399 3/20 0.52
GRIN2A Q12879 3/20 0.52
GRIN2C Q14957 3/20 0.52
GRIN3B O60391 2/20 0.52
GRIN3A Q8TCU5 2/20 0.52
ADRA2A P08913 5/20 0.50
HTR2A P28223 5/20 0.50
ADRA1A P35348 5/20 0.50
HTR2B P41595 4/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12588287 1.00 CYP2D6 (0.55) CYP2D6KCNH2CYP1A2CYP3A4CYP2C9
SCHEMBL21093519 1.00 CYP2D6 (0.55) CYP2D6KCNH2CYP1A2CYP3A4CYP2C9
SCHEMBL21758873 0.98 CYP2D6 (0.54) CYP2D6KCNH2CYP1A2CYP3A4CYP2C9
SCHEMBL2714385 0.98 CYP2D6 (0.54) CYP2D6KCNH2CYP1A2CYP3A4CYP2C9
SCHEMBL2699322 0.98 CYP2D6 (0.54) CYP2D6KCNH2CYP1A2CYP3A4CYP2C9
SCHEMBL2712368 0.98 CYP2D6 (0.54) CYP2D6KCNH2CYP1A2CYP3A4CYP2C9
SCHEMBL597166 0.98 CYP2D6 (0.54) CYP2D6KCNH2CYP1A2CYP3A4CYP2C9
SCHEMBL21093474 0.98 CYP2D6 (0.54) CYP2D6KCNH2CYP1A2CYP3A4CYP2C9
SCHEMBL523547 0.98 CYP2D6 (0.54) CYP2D6KCNH2CYP1A2CYP3A4CYP2C9
SCHEMBL2714074 0.98 CYP2D6 (0.54) CYP2D6KCNH2CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2627627-B1 PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS BRISTOL MYERS SQUIBB CO (US) 2017-08-09 EP claimed
EP-2627627-B1 PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS BRISTOL MYERS SQUIBB CO (US) 2017-08-09 EP disclosed
EP-2627643-B1 PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES BRISTOL MYERS SQUIBB CO (US) 2016-11-23 EP disclosed
US-20160326101-A1 Process for the Synthesis of Chiral Propargylic Alcohols BRISTOL MYERS SQUIBB CO (US) 2016-11-10 US disclosed
US-8969550-B2 Process for the synthesis of cyclic carbamates LONZA LTD. (CH) 2015-03-03 US disclosed
US-8957204-B2 Process for the synthesis of cyclic carbamates LONZA LTD. (CH) 2015-02-17 US disclosed
EP-2627642-B1 PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES LONZA AG (CH) 2014-12-24 EP disclosed
US-20130324763-A1 PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS LONZA LTD (CH) 2013-12-05 US disclosed
US-20130217875-A1 PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES LONZA LTD (CH) 2013-08-22 US disclosed
EP-2627642-A1 PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES Lonza Ltd (CH) 2013-08-21 EP disclosed
US-20130211077-A1 PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES LONZA LTD (CH) 2013-08-15 US disclosed
WO-2012097510-A1 PROCESS FOR PREPARATION OF EFAVIRENZ BY CYCLISATION LONZA LTD (CH) 2012-07-26 WO disclosed
WO-2012097511-A1 DMP-266 BY CYCLISATION LONZA LTD (CH) 2012-07-26 WO disclosed
EP-2447255-A1 Process for the synthesis of cyclic carbamates Lonza Ltd. (CH) 2012-05-02 EP disclosed
EP-2447247-A1 Process for the synthesis of chiral propargylic alcohols Lonza Ltd. (CH) 2012-05-02 EP disclosed
WO-2012048886-A1 PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES LONZA LTD (CH) 2012-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160326101-A1 Process for the Synthesis of Chiral Propargylic Alcohols ADH1C, ADH1A, ADH5 CYP2D6 622/4885KCNH2 3738/4885CYP1A2 112/4885
US-20130217875-A1 PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES PLCG2, PLCG1, CPS1 CYP2D6 723/4885KCNH2 1603/4885CYP1A2 640/4885
US-20130324763-A1 PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS ADH1C, ADH1A, ADH5 CYP2D6 622/4885KCNH2 3738/4885CYP1A2 112/4885
US-20130211077-A1 PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES PLCG2, PLCG1, PLCB1 CYP2D6 949/4885KCNH2 1263/4885CYP1A2 712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.